Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) reported revenue ahead of Wall Street’s expectations in calendar Q3 2026 (fiscal Q1 2027), with revenue up 6.3% year on year to $386.8 million. The company expects the full year’s revenue to be around $1.58 billion, close to analysts’ consensus estimates. Its non-GAAP profit of $0.79 per share was in line with analysts’ consensus estimates.
For more on Phibro Animal Health, read our free full research report.
Phibro Animal Health (PAHC) Q3 CY2026 highlights:
- Revenue $386.8 million vs S&P analysts’ consensus estimates of $375.4 million (6.3% year-on-year growth, 3% beat)
- Adjusted EPS $0.79 vs S&P analysts’ consensus estimates of $0.78 (in line)
- Adjusted EBITDA $64.3 million (16.6% margin, 3.9% year-on-year growth)
- Revenue guidance The company reconfirmed its revenue guidance for the full year of $1.58 billion at the midpoint
- Adjusted EPS guidance Management reiterated its full-year adjusted EPS guidance of $3.50 at the midpoint
- EBITDA guidance $263 million at the midpoint for the full year, above analysts’ consensus estimates of $259.6 million
- Operating margin 12.8%, down from 14.1% in the same quarter last year
- Market capitalization $1.53 billion
“We are pleased with our start to fiscal 2027,” said Dani Bendheim, President and Chief Executive Officer of Phibro Animal Health Corporation. “First quarter results exceeded our expectations and grew on top of a strong first quarter last year. The outperformance was led largely by a strong start to the year in Mineral Nutrition and Performance Products while our core Animal Health business delivered sales in line with our plan and Adjusted EBITDA ahead of plan, including the benefit of certain costs that shifted into the second quarter.”
Revenue growth
A company’s long-term revenue performance is one signal of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Phibro Animal Health grew its revenue at a solid 12.6% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Phibro Animal Health’s annualized revenue growth of 21.3% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated. 
This quarter, Phibro Animal Health reported year-on-year revenue growth of 6.3%, and its $386.8 million in revenue exceeded Wall Street’s consensus estimates by 3%.
Looking ahead, sell-side analysts expect revenue to grow 2.9% over the next 12 months, according to S&P, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will see some demand headwinds.
Adjusted operating margin
Adjusted operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses, from the cost of goods sold to advertising and wages. It’s also useful for comparing profitability across companies because it excludes non-recurring expenses, interest on debt and taxes.
Phibro Animal Health has done a decent job managing its cost base over the last five years. The company has produced an average adjusted operating margin of 10.8%, higher than the broader healthcare sector.
Phibro Animal Health’s adjusted operating margin rose by 4.9 percentage points over the last five years, as its revenue growth gave it operating leverage. The company’s two-year trajectory shows its performance was mostly driven by its recent improvements.
This quarter, Phibro Animal Health generated an adjusted operating margin of 12.8%, in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.
Earnings per share
Long-term changes in earnings per share, or EPS, matter for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
Phibro Animal Health’s EPS grew at a 21.2% compounded annual growth rate over the last five years, higher than its 12.6% annualized revenue growth. This indicates the company became more profitable on a per-share basis as it expanded.
A closer look at Phibro Animal Health’s earnings helps explain the drivers of its performance. As mentioned earlier, Phibro Animal Health’s adjusted operating margin was flat this quarter but expanded by 4.9 percentage points over the last five years. This was the most relevant factor, aside from the revenue impact, behind its higher earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.
In Q3, Phibro Animal Health reported adjusted EPS of $0.79, up from $0.73 in the same quarter last year. This result was close to analysts’ consensus estimates. Over the next 12 months, Wall Street expects Phibro Animal Health’s full-year EPS to grow 8.1% from $3.27 to $3.54, according to S&P.
Key takeaways from Phibro Animal Health’s Q3 results
Phibro Animal Health delivered some key positives, with revenue above analysts’ consensus estimates and full-year EBITDA guidance slightly ahead of Wall Street’s consensus. Shares remained flat at $39.19 immediately after the release.
When deciding whether to buy the stock, consider the broader picture. What happened in the latest quarter matters, but not as much as longer-term business quality and valuation. For more, read the full research report here (it’s free).